Iodinated contrast media and contrast-induced nephropathy: Is there a preferred cost-effective agent?

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Over 20 years have passed since the introduction of the tri-iodinated low-osmolar nonionic contrast agents such as iopamidol, iohexol, ioversol and iopromide. During this time, most cardiology practices have switched to these nonionic agents to avoid the nuisance side effects and cardiac adverse events associated with the older ionic contrast agents. Although the improved tolerability of the nonionic agents is generally attributed to their decreased osmolality (approximately half that of the older ionic contrast agents), in fact, these contrast agents also differ from the older agents in their ionicity, viscosity and direct chemotoxicity. The impact of these properties on safety, together with cost differences, should be considered when selecting a contrast agent.

Original languageEnglish
Pages (from-to)245-248
Number of pages4
JournalJournal of Invasive Cardiology
Volume20
Issue number5
StatePublished - May 2008

Fingerprint

Dive into the research topics of 'Iodinated contrast media and contrast-induced nephropathy: Is there a preferred cost-effective agent?'. Together they form a unique fingerprint.

Cite this